Report on the discrepancies between consensus documents, clinical practice guidelines and legal regulations in the treatment of type 2 diabetes;A propósito de las discrepancias entre documentos de consenso, guías de práctica clínica y normativa legal en el tratamiento de la diabetes tipo 2

Nefrologia

Volumn 32, Issue 4, 2012, Pages 419-426

  Martínez Castelao, Alberto ^a   Górriz, José L ^b   Sola, Eva ^b   Morillas, Carlos ^b   Jover, Ana ^b   Coronel, Francisco ^c   Navarro González, Juan ^d   De Álvaro, Fernando ^e  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^c HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^d HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE CANDELARIA   (Spain)

^e HOSPITAL UNIVERSITARIO INFANTA SOFÍA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; METFORMIN;

CONSENSUS DEVELOPMENT; DIABETIC NEPHROPATHY; DISEASE MANAGEMENT; FEMALE; HUMAN; MALE; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; PRACTICE GUIDELINE; PROFESSIONAL PRACTICE; STANDARD;

CONSENSUS DEVELOPMENT CONFERENCES AS TOPIC; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE MANAGEMENT; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; PRACTICE GUIDELINES AS TOPIC; PROFESSIONAL PRACTICE;

EID: 84868624846     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: 10.3265/Nefrologia.pre2012.Jun.11576     Document Type: Editorial

References (25)

1. Pozo-Fernández C, Pardo-Ruiz C, Sánchez-Botella C, Blanes-Castañer V, López-Menchero R, Gisbert-Sellés C, et al. Discrepancias entre documentos de consenso, guías, práctica clínica y normativa legal en el tratamiento de los pacientes con diabetes mellitus tipo 2. Nefrologia 2012;32:367-73.
2. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35(6):1364-79.
3. American Diabetes Association. Standards of medical care in diabetes-2012 (Position Statement). Diabetes Care 2012; 35 (Suppl1):S11-63.
4. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holmann RR, Sherwin R, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2008;31:173-5.
5. Menéndez Torre E, Lafita Tejedor J, Artola Menéndez S, Millán Núñez-Cortés J, Alonso García Á, Puig Domingo M, et al. Recomendaciones para el tratamiento farmacológico de la hiperglucemia en la diabetes tipo 2. Av Diabetol 2010;26:331-8.
6. NICE. Type 2 diabetes: the management of type 2 diabetes: NICE clinical guideline 87. National Institute of Health and clinical Excellence, 2009.
7. Shaw JS, Wilmot RL, Kilpatrick ES. Establishing pragmatic estimated GFR thresholds to guide metformin prescribing. Diabet Med 2007;24:1160-3.
8. Duong JK, Roberts DM, Furlong TJ, Kumar SS, Greenfield JR, Kirkpatrick CM, et al. Metformin therapy in patients with chronic kidney disease. Diabetes Obes Metab 2012. Doi: 10.1111/j.1463-1326.2012.01617.x. [Epub ahead of print].
9. Lipska KJ, Bailey CJ, Inzucchi SE. Use of metformin in the setting of mild-to-moderate renal Insufficiency. Diabetes Care 2011;34:1431-7.
10. Schumacher S, Abbasi I, Weise D, Hatorp V, Sattler K, Sieber J, et al. Single and multiple dose pharmacokinetics of repaglinide in patients with type 2 diabetes and renal impairment. Eur J Clin Pharmacol 2001;57:147-52.
11. Nagai T, Imamura M, Iizuka K, Mori M. Hypoglycaemia due to nateglinide administration in diabetic patients with chronic renal failure. Diabetes Res Clin Pract 2003;59:191-4.
12. Chan JC, Scott R, Ferreria JC, Sheng D, Gonzalez E, Davies MJ, et al. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes Obes Metab 2008;10:545-55.
13. Scott R, Hartley P, Luo E. Use of sitagliptin in patients with type 2 diabetes (T2DM) and renal insufficiency (RI). Diabetes 2006;55 (Suppl 1):A462.
14. Nowicki M, Rychlik L, Haller H, Warren ML, Suchower L, Gause-Nilsson I, et al. Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment. Diabetes Obes Metab 2011;13:523-32.
15. Lukashevich V, Schweizer A, Shao Q, Groop PH, Kothny W. Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial. Diabetes Obes Metab 2011;13:947-54.
16. Graefe-Mody U, Friedrich C, Port A, Ring A, Retlich S, Heise T, et al. Effect of renal impairment on the pharmacokinetics of the dipeptidylpeptidase-4 inhibidor linagliptin. Diabetes Obes Metab 2011;13:939-46.
17. Ito M, Abe M, Okada K, Sasaki H, Maruyama N, Tsuchida M, et al. The dipeptidyl peptidase-4 (DPP-4) inhibitor vildagliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis. Endocr J 2011;58:979-87.
18. Charpentier G, Riveline JP, Varroud-Vial M. Management of drugs affecting blood glucose in diabetic patients with renal failure. Diabetes Metab 2000;26:73-85.
19. Snyder RW, Berns JS. Use of insulin and oral hypoglycemic medications in patients with diabetes mellitus and advanced kidney disease. Semin Dial 2004;17:365-70.
20. Tunbridge FK, Newens A, Home PD, Davis SN, Murphy M, Burrin JM, et al. A comparison of human ultralente- and lente-based twicedaily injection regimens. Diabet Med 1989;6:496-501.
21. Freeman SL, O'Brien PC, Rizza RA. Use of human ultralente as the basal insulin component in treatment of patients with IDDM. Diabetes Res Clin Pract 1991;12:187-92.
22. Selgas R. Comparative study of two different routes for insulin administration in CAPD patients: A multicenter study. Adv Perit Dial 1988;4:126-30.
23. Coronel F, Naranjo P, Serrano R, Cruceyra A, Prats D. Eficacia de la administración de insulina intraperitoneal en diabéticos sometidos a diálisis peritoneal continua ambulatoria. Med Clin (Barc) 1984;82:881-4.
24. Fine A, Parry D, Ariano R, Dent W. Marked variation in peritoneal insulin absorption in peritoneal dialysis. Perit Dial Int 2000;20:652-5.
25. Jacobsen LV, Hindsberger C. Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide. Br J Clin Pharmacol 2009;68:898-905.